Skip to main content
    N

    Novavax Inc (NVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.96
    -0.10 (-1.24%)

    Market Cap: $1.33B

    Last updated: Nov 17, 2026 at 4:41 PM ET

    Novavax Inc (NVAX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Novavax (NVAX) has a market cap of $1.33B and an enterprise value of $1.40B. Revenue fell 61.33% over the last 12 months from the 12 months before. It kept -18.64% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 5.24% above the market cap, as debt exceeds cash.

    Market Cap$1.33B
    Enterprise Value$1.40B
    Latest price (Nov 17, 2026)$7.96

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.21% in the quarter ended Sep 30, 2026 and grew 1.51% a year over 2 years.

    Shares Outstanding164.92M
    Shares Change (YoY)+1.58%
    Shares Change (QoQ)+0.21%
    Share Count Growth (2Y CAGR)+1.51%

    Valuation Ratios

    The price to sales ratio is 3.2x. Its year-end P/S ranged from 0.4x to 455.3x from 2016 to 2025.

    P/S Ratio3.2x
    Forward P/S2.8x

    Price Statistics

    The stock is up 14.20% over 52 weeks and trades 23.83% below its 50-day average.

    Beta (1Y)2.10
    52-Week Change+14.20%
    1-Month Change-26.43%
    3-Month Change-9.44%
    6-Month Change-10.56%
    5-Year Change-93.23%
    10-Year Change-66.84%
    Total Return (1Y)+14.20%
    Total Return (3Y CAGR)+11.58%
    Total Return (5Y CAGR)-47.06%
    Return vs SPY (1Y)+9.60%
    Max Drawdown (1Y)-37.91%
    Max Drawdown (3Y)-74.11%
    Sharpe Ratio (1Y)0.27
    Correlation with SPY (1Y)0.40
    50-Day Average$10.45
    200-Day Average$9.33
    52-Week Range$6.20 to $13.39
    RSI (14 Days)34.7
    Average Volume (20 Days)6.01M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.15x current liabilities.

    Current Ratio2.15x
    Quick Ratio2.09x
    Interest Coverage9.63x

    Returns and Efficiency

    Return on invested capital is -66.62% over the last 12 months.

    Return on Assets (ROA)-8.64%
    Return on Invested Capital (ROIC)-66.62%
    Return on Capital Employed (ROCE)-8.98%
    ROA (5Y Average)-20.34%
    Asset Turnover0.40x
    Inventory Turnover6.35x
    Receivables Turnover12.13x
    Cash Conversion Cycle-9 days

    Scores

    NVAX has an Altman Z-Score of -5.85, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score-5.85
    Altman Z ZoneDistress
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $411.65M over the last 12 months.

    Revenue$411.65M
    Revenue Growth (YoY)-61.33%
    Gross Profit$321.12M
    Operating Income-$87.39M
    Pretax Income-$71.93M
    Net Income-$76.73M
    EBITDA-$35.83M
    EBIT-$50.12M
    Reported EPS (TTM)-$0.46

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$222.46M
    Total Debt$292.09M
    Net Debt$69.63M
    Net Debt Per Share$0.42
    Working Capital$378.11M
    Shareholder Equity-$216.85M
    Tangible Book Value-$328.93M
    Total Assets$888.00M
    Total Liabilities$1.10B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $5.13M of capital spending, operating cash flow left -$244.07M of free cash flow.

    Operating Cash Flow-$238.95M
    Capital Expenditures$5.13M
    Free Cash Flow-$244.07M
    FCF Per Share-$1.48
    Depreciation and Amortization$14.29M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -21.23%, against a 5-year average of -46.69%.

    Gross Margin78.01%
    Operating Margin-21.23%
    Pretax Margin-17.47%
    Net Margin-18.64%
    EBITDA Margin-8.70%
    EBIT Margin-12.17%
    FCF Margin-59.29%
    Gross Margin (5Y Average)76.66%
    Operating Margin (5Y Average)-46.69%
    Net Margin (5Y Average)-45.80%

    Growth

    Revenue fell 17.24% a year over 3 years.

    Revenue Growth (3Y CAGR)-17.24%
    Revenue Growth (5Y CAGR)+18.76%

    Revenue and profit by year

    Dividends and Yields

    NVAX does not pay a dividend. Its free cash flow yield is -18.59%.

    FCF Yield-18.59%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-20 reverse split on May 10, 2019.

    Last Split DateMay 10, 2019
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 10 similar companies, NVAX has the 7th highest P/S.

    P/S Ratio3.2x vs 5.1x median
    ROIC-66.62% vs -28.26% median
    Revenue Growth (Trailing 4 Quarters, YoY)-61.33% vs +12.82% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -53.20% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-53.20%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About NVAX

    What is NVAX's market cap?

    Novavax has a market cap of $1.33B. Its enterprise value, which adds debt and subtracts cash, is $1.40B.

    How many shares of NVAX are outstanding?

    Novavax has 164.92M shares outstanding. The count is up 1.58% from a year earlier.

    Does NVAX pay a dividend?

    No. Novavax does not pay a dividend.

    How much debt does NVAX have?

    Novavax has $292.09M of total debt and $222.46M of cash and equivalents, a net debt position of $69.63M.